Company: HROW
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001641172-25-006102
Chunk: 35

Company: HARROW, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 35
---
 surgical device and diagnostic product portfolios. Prior to joining the Company, he served as Head of U.S. Marketing and Strategy for ThromboGenics Inc., developing the commercial strategy and building a team to launch a new biologic into the U.S. market. Prior to that he was Vice President, Business Development at SurModics Inc., working with both large and small pharmaceutical companies on multi-platform drug delivery initiatives in the U.S. and internationally. Earlier in his career, he held positions of increasing responsibility in both marketing and sales at a number of companies, including his tenure with Bausch & Lomb. Mr. Saharek has a Master of Business Administration in Finance from the University of Hartford and a Bachelor of Arts in Business from Central Connecticut State University.

Amir H. Shojaeijoined the Company as its Chief Scientific Officer in January 2025, where he has management and oversight of all development, clinical, medical and regulatory affairs activities for Harrow’s marketed ophthalmic branded products. From 2021 to 2024, Dr. Shojaei was the Chief Scientific Officer & Executive Vice President, Clinical Development of AsclepiX Therapeutics, a development stage company developing therapeutics for various ophthalmic related diseases. Prior to that, he held senior executive roles at leading pharmaceutical companies, including Chief Executive Officer of TherOptix Corporation, where he advanced a novel drug-eluting contact lens platform, and in various leadership roles at TearClear Corporation, Novartis Pharmaceuticals and Shire Pharmaceuticals (acquired by Takeda). In 2013, while at Shire Pharmaceuticals, Dr. Shojaei was instrumental in the clinical development and the eventual FDA approval of Xiidra®, the first product approved to treat both the signs and symptoms of dry eye disease (DED). Dr. Shojaei earned his Ph.D, Pharmaceutics and Doctor of Pharmacy magna cum laudefrom the University of Pacific and Bachelor of Science in Biological Sciences from the University of Alberta.

| Harrow, Inc. 2025 Proxy Statement | 19 |

<div align='center'>DIRECTOR COMPENSATION</div>

Director Compensation Program for Year Ended December 31, 2024

A summary of the non-employee director compensation arrangements for 2024 is set forth below.

Cash Compensation

|                                                                 |     | Retainer and Meeting Fees |        |
|:----------------------------------------------------------------|:----|:--------------------------|-------:|
| Annual Board Retainer Fee                                       |     | $                         | 50,